declares having received research grants through his affiliation from Novo Nordisk and Pharmaserve Lilly, and consulting honoraria from Pharmaserve Lilly, Sanofi-Aventis, Novo Nordisk, MSD, AstraZeneca, ELPEN Pharma, Boehringer Ingelheim, Galenica Pharma, Epsilon Health and WinMedica
Clinical data shows combining semaglutide with lifestyle changes results in greater weight loss than medication alone
The images or other third party material in this article are included in the articles Creative Commons license, unless indicated otherwise in a credit line to the material
Eva (08:38): Yeah, there's no artificial sweetener
9 February 2018
Cardiovascular disease remains the leading cause of morbidity and mortality in patients with diabetes, and interventions that can mitigate this risk are invaluable